Takeda Pharmaceutical Co. has agreed to pay up to $2.4 billion to resolve bladder cancer claims tied to its Type 2 diabetes drug Actos. The settlement will compensate an estimated 10,000 cla... Read more
As we mentioned above, lawyers in the Mass Torts Section at Beasley Allen continue to evaluate and file claims involving bladder cancer during or following usage of Actos, Actoplus Met, Acto... Read more
U.S. District Judge Rebecca Doherty has rejected the attempt by Takeda Pharmaceutical Co. and Eli Lilly & Co. to get the combined $9 billion punitive-damage award returned by a jury thro... Read more
A federal jury in Lafayette, La., last month ordered Takeda Pharmaceutical Co., based in Osaka, Japan, and its partner, Eli Lilly & Co, based in Indianapolis, Ind., to pay a combined $9... Read more
The first federal Actos trial is underway in Lafayette, La., before Judge Rebecca Doherty. Following jury selection, which took place the week before, the trial started on Feb. 4 and was ong... Read more
Beasley Allen lawyers continue to pursue Actos claims on behalf of individuals who have been diagnosed with bladder cancer after using Actos to treat their type 2 diabetes. Andy Birchfield a... Read more
Actos lawsuits filed on behalf of patients who developed bladder cancer linked to use of the Type 2 diabetes drug continue to move forward in a multi-district litigation (MDL) underway in th... Read more
Lawyers in our Mass Torts Section have been heavily involved in the litigation involving Actos, the diabetes drug. In June 2011, the FDA warned the public that Actos usage for more than one... Read more
In the first of more than 3,000 Actos bladder cancer lawsuits to go trial, a jury returned a $6.5 million verdict last month against Takeda Pharmaceuticals American Inc. in favor of Jack Coo... Read more
In June 2011, the FDA warned the public that Actos usage for more than one year may be associated with an increased risk of bladder cancer. Actos, manufactured by Takeda, is in a class of in... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.